Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
US-based Celcuity has announced a new clinical trial collaboration and supply agreement with Bayer to provide its cancer drug Nubeqa (darolutamide) for a planned Phase Ib/II clinical trial. Free Buyers GuideCelcuity teams up with Bayer for Phase Ib/II prostate cancer trialThe document includes detailed information on the manufacturers and suppliers and their products, along with contact details, to inform your purchasing decision. Thank you.Your download email will arrive shortly.While you wait why not take a look at other free recommend buyer’s guides Download free guide
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with VMS Engage-Buyer's Guide and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
View allCompanies IntelligencePfizer IncBayer AGAstraZeneca PlcCelcuity IncView all
The Phase Ib/II CELC-G-201 study will recruit up to 54 participants who progressed after treatment with an androgen receptor inhibitor (ARI) as first-line treatment for mCRPC. The company plans to randomly assign 36 participants to receive 600mg of Nubeqa in combination with either 120mg gedatolisib in arm one or 180mg gedatolisib in arm two. Later, in Phase II, 12 more participants will be enrolled to study the radiographic progression-free survival (rPFS) at six months of patients who received the recommended Phase II dose. In a 22 August press release, Celcuity CEO Brian Sullivan said: “Darolutamide is structurally unique to other ARIs, with excellent efficacy and differentiated tolerability profile coupled with minimal drug-drug interactions, making it an ideal combination partner for gedatolisib. Free Buyers GuideTop Guide for Clinical Trials and Development ServicesThe document includes detailed information on the manufacturers and suppliers and their products, along with contact details, to inform your purchasing decision.
Thank you.Your download email will arrive shortly.While you wait why not take a look at other free recommend buyer’s guides
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with VMS Engage-Buyer's Guide and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.